PT  - JOURNAL ARTICLE
AU  - Satoshi Okamori
AU  - Eisaku Tanaka
AU  - Nobuyoshi Hamao
AU  - Yuto Yasuda
AU  - Takashi Inao
AU  - Chie Morimoto
AU  - Ikkou Yasuda
AU  - Yusuke Kaji
AU  - Takehiro Yasuda
AU  - Seishu Hashimoto
AU  - Takashi Hajiro
AU  - Yoshio Taguchi
TI  - Nontuberculous mycobacterial infection in chronic obstructive pulmonary disease
AID  - 10.1183/13993003.congress-2015.PA569
DP  - 2015 Sep 01
TA  - European Respiratory Journal
PG  - PA569
VI  - 46
IP  - suppl 59
4099  - http://erj.ersjournals.com/content/46/suppl_59/PA569.short
4100  - http://erj.ersjournals.com/content/46/suppl_59/PA569.full
SO  - Eur Respir J2015 Sep 01; 46
AB  - Background: Nontuberculous mycobacterial (NTM) lung disease secondary to cystic fibrosis has been reported, but there is limited data about NTM associated with chronic obstructive pulmonary disease (COPD).Aims and Objectives: The aim of our study is to clarify the prevalence and characteristics of NTM lung disease in COPD patients.Methods: We reviewed mycobacterial cultures of 1,640 patients with COPD who visited out hospital between January 2007 and December 2012.Results: 43 patients (2.6%) satisfied the diagnostic criteria of NTM lung disease presented in the official ATS/IDSA statement. The most frequent species was Mycobacterium avium (24 patients, 55.8%), followed by Mycobacterium intracellulare (6 patients, 14.0%). Mean age of NTM-positve patients was 68.6 ± 8.5 years and 3 patients (7.0%) were female, which were not significantly different from NTM-negative COPD patients. Body mass index, %FEV1 predicted and rate of inhaled corticosteroid user were not significantly different between NTM-positive and NTM-negative patients.Conclusions: Our observations suggest that NTM is found more often in COPD than general population. In our COPD patients, gender, body mass index, %FEV1 predicted and inhaled corticosteroid usage did not affect the NTM prevalence.